Determining diagnosis, assessing prognosis, and assigning appropriate therapy for patients with gliomas has traditionally relied on pathological and clinical factors. These factors include the age, sex, and performance status as well as tumor histologic type, pathologic grade, and specific location. Some of these factors are easy to assess while others, especially histologic type and grade, can be difficult and depend upon the interpretation of a skilled neuropathologist. Molecular genetic, cytogenetic, flow cytometric, and immunohistochemical factors have been used to assess many solid tumors including gliomas. During the initial grant period at Mayo several potential factors which may be useful in the classification of glial tumors have been identified The first goal of the next study period is: to determine if such factor can be used to classify astrocytic tumors of favorable and poor prognosis. The second goal is to develop markers which will reliably differentiate astrocytomas, oligodendrogliomas, and mixed oligoastrocytomas. Several groups of tumor specimens will be available to help achieve these goals: 1) the set of frozen gliomas prospectively obtained at Mayo during the initial and renewal project period, 2) sets of paraffin-embedded gliomas from patients entered on previous and current prospective clinical trials of the North Central Cancer Treatment Group (NCCTG) and the Radiation Therapy Oncology Group (RTOG), and 3) a large series of retrospectively ascertained paraffin-embedded gliomas previously treated at Mayo but not part of the preceding two groups.
The specific aims of this project are to: 1) to evaluate the diagnostic and prognostic relevance of alterations of specific chromosomes and chromosomal regions detected by polymerase chain reaction (PCR) analysis of microsatellite repeats and fluorescent in situ hybridization (FISH). 2) To evaluate the diagnostic and prognostic relevance of DNA ploidy by flow cytometric analysis and to compare this analysis with ploidy determination by FISH. 3) To assess the diagnostic and prognostic relevance of various markers of cellular proliferation and cellular function including flow cytometric determination of %S-phase, %G2M, and immunohistochemical evaluation of PCNA, Ki67, and p53. 4) To evaluate molecular markers proposed by the other institutions supported by this cooperative agreement and to share techniques, tissues, and expertise with these institutions. The long-term objective of this project is to assess and utilize molecular markers to more accurately classify and grade gliomas and thus improve the prediction of prognosis and the assignment of optimal therap for patients with these tumors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
3U01CA050905-09S1
Application #
6013868
Study Section
Special Emphasis Panel (SRC (90))
Program Officer
Jacobson, James W
Project Start
1995-01-13
Project End
2001-11-30
Budget Start
1997-12-01
Budget End
2001-11-30
Support Year
9
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Buckner, Jan C; Gesme Jr, Dean; O'Fallon, Judith R et al. (2003) Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21:251-5
Popko, Brian; Pearl, Dennis K; Walker, Diane M et al. (2002) Molecular markers that identify human astrocytomas and oligodendrogliomas. J Neuropathol Exp Neurol 61:329-38
Kuriyama, Hiroko; Lamborn, Kathleen R; O'Fallon, Judith R et al. (2002) Prognostic significance of an apoptotic index and apoptosis/proliferation ratio for patients with high-grade astrocytomas. Neuro Oncol 4:179-86
Smith, J S; Tachibana, I; Passe, S M et al. (2001) PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93:1246-56
Burger, P C; Pearl, D K; Aldape, K et al. (2001) Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? J Neuropathol Exp Neurol 60:1099-104
Burger, P C; Minn, A Y; Smith, J S et al. (2001) Losses of chromosomal arms 1p and 19q in the diagnosis of oligodendroglioma. A study of paraffin-embedded sections. Mod Pathol 14:842-53
Nigro, J M; Takahashi, M A; Ginzinger, D G et al. (2001) Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol 158:1253-62
Smith, J S; Wang, X Y; Qian, J et al. (2000) Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features. J Neuropathol Exp Neurol 59:495-503
Pohl, U; Smith, J S; Tachibana, I et al. (2000) EHD2, EHD3, and EHD4 encode novel members of a highly conserved family of EH domain-containing proteins. Genomics 63:255-62
Smith, J S; Tachibana, I; Pohl, U et al. (2000) A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics 64:44-50

Showing the most recent 10 out of 39 publications